153 related articles for article (PubMed ID: 36484721)
1. HRS Regulates Small Extracellular Vesicle PD-L1 Secretion and Is Associated with Anti-PD-1 Treatment Efficacy.
Xiao BL; Wang XL; Xia HF; Zhang LZ; Wang KM; Chen ZK; Zhong YH; Jiang HG; Zhou FX; Wang W; Chen GL; Chen G
Cancer Immunol Res; 2023 Feb; 11(2):228-240. PubMed ID: 36484721
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive effect of small extracellular vesicle PD-L1 is restricted by co-expression of CD80.
Liu JY; Yu ZL; Fu QY; Zhang LZ; Li JB; Wu M; Liu B; Chen G
Br J Cancer; 2023 Oct; 129(6):925-934. PubMed ID: 37532831
[TBL] [Abstract][Full Text] [Related]
3. PD-L1-positive circulating endothelial progenitor cells associated with immune response to PD-1 blockade in patients with head and neck squamous cell carcinoma.
Su NW; Dai SH; Hsu K; Chang KM; Ko CC; Kao CW; Chang YF; Chen CG
Cancer Immunol Immunother; 2024 Jan; 73(1):3. PubMed ID: 38175307
[TBL] [Abstract][Full Text] [Related]
4. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
Mao L; Xiao Y; Yang QC; Yang SC; Yang LL; Sun ZJ
Oral Oncol; 2021 Oct; 121():105472. PubMed ID: 34333450
[TBL] [Abstract][Full Text] [Related]
5. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
[TBL] [Abstract][Full Text] [Related]
6. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
[TBL] [Abstract][Full Text] [Related]
7. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
8. Melatonin inhibits EMT and PD-L1 expression through the ERK1/2/FOSL1 pathway and regulates anti-tumor immunity in HNSCC.
Luo X; Chen Y; Tang H; Wang H; Jiang E; Shao Z; Liu K; Zhou X; Shang Z
Cancer Sci; 2022 Jul; 113(7):2232-2245. PubMed ID: 35298069
[TBL] [Abstract][Full Text] [Related]
9. WJMSC-derived small extracellular vesicle enhance T cell suppression through PD-L1.
Li M; Soder R; Abhyankar S; Abdelhakim H; Braun MW; Trinidad CV; Pathak HB; Pessetto Z; Deighan C; Ganguly S; Dawn B; McGuirk J; Dunavin N; Godwin AK
J Extracell Vesicles; 2021 Feb; 10(4):e12067. PubMed ID: 33598108
[TBL] [Abstract][Full Text] [Related]
10. PD-1 Carried on Small Extracellular Vesicles Leads to OSCC Metastasis.
Zhang LZ; Yang JG; Xia HF; Huang J; Liu HM; Wu M; Liu B; Wang WM; Chen G
J Dent Res; 2023 Jul; 102(7):795-805. PubMed ID: 37246810
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Immunoregulatory Biomarkers on Plasma Small Extracellular Vesicles for Disease Progression and Early Therapeutic Response in Head and Neck Cancer.
Jablonska J; Rist M; Spyra I; Tengler L; Domnich M; Kansy B; Giebel B; Thakur BK; Rotter N; Lang S; Ludwig S
Cells; 2022 Mar; 11(5):. PubMed ID: 35269524
[TBL] [Abstract][Full Text] [Related]
12. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
13. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
[TBL] [Abstract][Full Text] [Related]
14. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
Front Immunol; 2020; 11():1721. PubMed ID: 33072064
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance.
Bhola NE; Njatcha C; Hu L; Lee ED; Shiah JV; Kim MO; Johnson DE; Grandis JR
Head Neck; 2021 Nov; 43(11):3364-3373. PubMed ID: 34346116
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma.
Evrard D; Hourseau M; Couvelard A; Paradis V; Gauthier H; Raymond E; Halimi C; Barry B; Faivre S
Oncoimmunology; 2020 Nov; 9(1):1844403. PubMed ID: 33299655
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
[TBL] [Abstract][Full Text] [Related]
18. SN-38, an active metabolite of irinotecan, enhances anti-PD-1 treatment efficacy in head and neck squamous cell carcinoma.
Lee YM; Chen YH; Ou DL; Hsu CL; Liu JH; Ko JY; Hu MC; Tan CT
J Pathol; 2023 Apr; 259(4):428-440. PubMed ID: 36641765
[TBL] [Abstract][Full Text] [Related]
19. PD-1/CD80
Zhang LZ; Yang JG; Chen GL; Xie QH; Fu QY; Xia HF; Li YC; Huang J; Li Y; Wu M; Liu HM; Wang FB; Yi KZ; Jiang HG; Zhou FX; Wang W; Yu ZL; Zhang W; Zhong YH; Bian Z; Yang HY; Liu B; Chen G
Nat Commun; 2024 May; 15(1):3884. PubMed ID: 38719909
[TBL] [Abstract][Full Text] [Related]
20. The prognosis of head and neck squamous cell carcinoma related to immunosuppressive tumor microenvironment regulated by IL-6 signaling.
Tsai MS; Chen WC; Lu CH; Chen MF
Oral Oncol; 2019 Apr; 91():47-55. PubMed ID: 30926062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
